{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:37:54Z","timestamp":1792730274292,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"DOI":"10.1007\/s40265-026-02394-y","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:56:59Z","timestamp":1792727819000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Gedatolisib: First Approval"],"prefix":"10.1007","author":[{"given":"Hannah A.","family":"Blair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"issue":"9","key":"2394_CR1","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1007\/s40265-026-02347-5","volume":"86","author":"L Lei","year":"2026","unstructured":"Lei L, Canning M, Sakach E, et al. Emerging strategies targeting the PI3K\/AKT\/mTOR pathway in HR+\/HER2\u2212 advanced breast cancer. Drugs. 2026;86(9):1471\u201387.","journal-title":"Drugs"},{"issue":"1","key":"2394_CR2","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano A, Foo ASC, Lam HY, et al. PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023;22(1):138.","journal-title":"Mol Cancer"},{"key":"2394_CR3","unstructured":"Celcuity Inc. Celcuity announces FDA acceptance of New Drug Application for gedatolisib in HR+\/HER2-\/PIK3CA wild-type advanced breast cancer [media release]. 20 Jan 2026. http:\/\/www.celcuity.com."},{"key":"2394_CR4","unstructured":"Celcuity Inc. REVTORPYK (gedatolisib) for injection, for intravenous infusion: US prescribing information. 2026. https:\/\/www.celcuity.com\/wp-content\/uploads\/2026\/04\/REVTORPYK_PI_2026.pdf. Accessed 15 Sept 2026."},{"key":"2394_CR5","unstructured":"U.S. Food & Drug Administration. FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer [media release]. 14 July 2026. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-gedatolisib-fulvestrant-or-without-palbociclib-hr-positive-her2-negative-locally."},{"key":"2394_CR6","unstructured":"Celcuity Inc. Form 10-K for Celcuity INC filed 03\/23\/2022 & annual report 2021. SEC Filing Report; Company Report."},{"key":"2394_CR7","unstructured":"Celcuity Inc. Celcuity announces FDA breakthrough therapy designation for gedatolisib for treatment of HR+\/HER2\u2212 metastatic breast cancer [media release]. 18 July 2022. http:\/\/www.celcuity.com."},{"key":"2394_CR8","unstructured":"Celcuity Inc. Celcuity\u2019s phase 3 VIKTORIA-2 trial of gedatolisib as a first-line treatment for HR+\/HER2\u2212 advanced breast cancer expanding to include endocrine-sensitive patients [media release]. 14 May 2026. http:\/\/www.celcuity.com."},{"key":"2394_CR9","unstructured":"Celcuity Inc. Celcuity announces worldwide licensing agreement with Pfizer to develop and commercialize gedatolisib, a first-in-class PI3K\/mTOR inhibitor for breast cancer [media release]. 8 Apr 2021. http:\/\/www.celcuity.com."},{"key":"2394_CR10","unstructured":"Celcuity Inc. Celcuity announces clinical trial collaboration and supply agreement with Pfizer to provide Ibrance(R) (palbociclib) for planned phase 3 clinical trial [media release]. 15 Nov 2021. http:\/\/www.celcuity.com."},{"key":"2394_CR11","unstructured":"Celcuity Inc. Celcuity enters into a clinical trial collaboration and supply agreement with Bayer to provide Nubeqa\u00ae (darolutamide) for planned phase 1b\/2 clinical trial [media release]. 22 Aug 2023. http:\/\/www.celcuity.com."},{"key":"2394_CR12","unstructured":"Celcuity Inc. Form 10-K for Celcuity INC filed 03\/11\/2026 & annual report 2025. SEC Filing Report; Company Report."},{"key":"2394_CR13","unstructured":"Celcuity Inc. Celcuity announces issuance of new patent for gedatolisib that extends patent exclusivity into 2042 [media release]. 14 July 2025. http:\/\/www.celcuity.com."},{"issue":"10","key":"2394_CR14","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1158\/1078-0432.CCR-10-1694","volume":"17","author":"R Mallon","year":"2011","unstructured":"Mallon R, Feldberg LR, Lucas J, et al. Antitumor efficacy of PKI-587, a highly potent dual PI3K\/mTOR kinase inhibitor. Clin Cancer Res. 2011;17(10):3193\u2013203.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2394_CR15","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1021\/jm901830p","volume":"53","author":"AM Venkatesan","year":"2010","unstructured":"Venkatesan AM, Dehnhardt CM, Delos Santos E, et al. Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5\u2032-triphosphate competitive phosphatidylinositol-3-kinase\/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor. J Med Chem. 2010;53(6):2636\u201345.","journal-title":"J Med Chem"},{"issue":"1","key":"2394_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41523-024-00648-0","volume":"10","author":"S Rossetti","year":"2024","unstructured":"Rossetti S, Broege A, Sen A, et al. Gedatolisib shows superior potency and efficacy versus single-node PI3K\/AKT\/mTOR inhibitors in breast cancer models. NPJ Breast Cancer. 2024;10(1):1\u201315.","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"2394_CR17","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1002\/1878-0261.13703","volume":"19","author":"A Sen","year":"2025","unstructured":"Sen A, Khan S, Rossetti S, et al. Assessments of prostate cancer cell functions highlight differences between a pan-PI3K\/mTOR inhibitor, gedatolisib, and single-node inhibitors of the PI3K\/AKT\/mTOR pathway. Mol Oncol. 2025;19(1):225\u201347.","journal-title":"Mol Oncol"},{"issue":"20","key":"2394_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16203520","volume":"16","author":"A Broege","year":"2024","unstructured":"Broege A, Rossetti S, Sen A, et al. Functional assessments of gynecologic cancer models highlight differences between single-node inhibitors of the PI3K\/AKT\/mTOR pathway and a pan-PI3K\/mTOR inhibitor, gedatolisib. Cancers (Basel). 2024;16(20):3520.","journal-title":"Cancers (Basel)"},{"key":"2394_CR19","doi-asserted-by":"crossref","unstructured":"Rossetti S, Broege A, Davis L, et al. Functional analysis of gedatolisib combined with fulvestrant and\/or palbociclib in breast cancer cell models adapted to estrogen receptor and\/or CDK4\/6 inhibitors [abstract no. PS2-11-30 plus poster]. Clin Cancer Res. 2026;32(4_Suppl).","DOI":"10.1158\/1557-3265.SABCS25-PS2-11-30"},{"issue":"12","key":"2394_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26125844","volume":"26","author":"A Broege","year":"2025","unstructured":"Broege A, Rossetti S, Sen A, et al. Functional analysis of the PI3K\/AKT\/mTOR pathway inhibitor, gedatolisib, plus fulvestrant with and without palbociclib in breast cancer models. Int J Mol Sci. 2025;26(12):5844.","journal-title":"Int J Mol Sci"},{"key":"2394_CR21","doi-asserted-by":"crossref","unstructured":"Pistilli B, Hurvitz SA, Gunn L, et al. Assessment of gedatolisib (geda) pharmacokinetics (PK), drug\u2013drug interactions (DDI), and exposure-safety and exposure\u2013efficacy relationships [abstract no. e13069]. J Clin Oncol. 2026;44(16_Suppl).","DOI":"10.1200\/JCO.2026.44.16_suppl.e13069"},{"issue":"12","key":"2394_CR22","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1200\/JCO-25-02643","volume":"44","author":"SA Hurvitz","year":"2026","unstructured":"Hurvitz SA, Layman RM, Curigliano G, et al. VIKTORIA-1 trial of gedatolisib plus fulvestrant with or without palbociclib in hormone receptor\u2013positive\/HER2\u2212\/PIK3CA wild-type advanced breast cancer. J Clin Oncol. 2026;44(12):1108\u201319.","journal-title":"J Clin Oncol"},{"key":"2394_CR23","doi-asserted-by":"crossref","unstructured":"Hurvitz SA, Curigliano G, Andre F, et al. A randomized, open-label, phase 3 study of gedatolisib + fulvestrant \u00b1 palbociclib vs standard of care in HR+\/HER2\u2212\/PIK3CA-mutant (MT) advanced breast cancer (VIKTORIA-1 study 2) [abstract no. LBA1008 plus presentation]. J Clin Oncol. 2026;44(17_Suppl).","DOI":"10.1200\/JCO.2026.44.17_suppl.LBA1008"},{"issue":"3","key":"2394_CR24","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s10549-025-07747-x","volume":"212","author":"S Phadke","year":"2025","unstructured":"Phadke S, Miller KD, Shah A, et al. Phase I\/II trial investigating gedatolisib plus talazoparib in advanced triple negative or BRCA1\/2 positive, HER2 negative breast cancers. Breast Cancer Res Treat. 2025;212(3):521\u201330.","journal-title":"Breast Cancer Res Treat"},{"key":"2394_CR25","doi-asserted-by":"crossref","unstructured":"Layman R, Wesolowski R, Han H, et al. Phase Ib expansion study of gedatolisib in combination with palbociclib and endocrine therapy in women with ER+ metastatic breast cancer [abstract no. PD13-02 plus poster]. Cancer Res. 2022;82(4_Suppl).","DOI":"10.1158\/1538-7445.SABCS21-PD13-02"},{"key":"2394_CR26","doi-asserted-by":"crossref","unstructured":"Forero-Torres A, Han H, Dees EC, et al. Phase Ib study of gedatolisib in combination with palbociclib and endocrine therapy (ET) in women with estrogen receptor (ER) positive (+) metastatic breast cancer (MBC) (B2151009) [abstract no. 1040]. J Clin Oncol. 2018;36(15_Suppl).","DOI":"10.1200\/JCO.2018.36.15_suppl.1040"},{"key":"2394_CR27","doi-asserted-by":"crossref","unstructured":"Wesolowski R, Rugo H, Stringer-Reasor E, et al. Updated results of a phase 1b study of gedatolisib plus palbociclib and endocrine therapy in women with hormone receptor positive advanced breast cancer: subgroup analysis by PIK3CA mutation status [abstract no. PD13-05 plus poster]. Cancer Res. 2023;83(5_Suppl).","DOI":"10.1158\/1538-7445.SABCS22-PD13-05"},{"issue":"15","key":"2394_CR28","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1158\/1078-0432.CCR-21-3078","volume":"28","author":"M Radovich","year":"2022","unstructured":"Radovich M, Solzak JP, Wang CJ, et al. Initial phase I safety study of gedatolisib plus cofetuzumab pelidotin for patients with metastatic triple-negative breast cancer. Clin Cancer Res. 2022;28(15):3235\u201341.","journal-title":"Clin Cancer Res"},{"issue":"Suppl 4","key":"2394_CR29","doi-asserted-by":"publisher","first-page":"S487","DOI":"10.1016\/j.annonc.2020.08.682","volume":"31","author":"I Colombo","year":"2020","unstructured":"Colombo I, Genta S, Martorana F. Phase I dose-escalation study of the dual PI3K\/mTORC1\/2 inhibitor gedatolisib (PF-05212384) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumours [abstract no. 568P]. Ann Oncol. 2020;31(Suppl 4):S487.","journal-title":"Ann Oncol"},{"key":"2394_CR30","doi-asserted-by":"crossref","unstructured":"Millham R, Houk B, Borzillo G, et al. First-in-patient study of PF-05212384, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: update on safety, efficacy, and pharmacology [abstract no. A167]. In: AACR-NCI-EORTA International Conference on Molecular Targets and Cancer Therapeutics. 2011.","DOI":"10.1158\/1535-7163.TARG-11-A167"},{"key":"2394_CR31","doi-asserted-by":"crossref","unstructured":"Hurvitz S, Pistilli B, Kaklamani V, et al. A randomized, open-label, phase 3 study of fulvestrant and CDK4\/6 inhibitors with or without gedatolisib as first-line treatment in patients with HR+\/HER2\u2212 advanced breast cancer (VIKTORIA-2) [abstract no. CT258]. Cancer Res. 2025;85(8_Suppl_2).","DOI":"10.1158\/1538-7445.AM2025-CT258"},{"issue":"Suppl 2","key":"2394_CR32","first-page":"S1309","volume":"36","author":"A Bernard-Tessier","year":"2025","unstructured":"Bernard-Tessier A, Piulats JM, Esteban-Villarrubia J, et al. Phase I\/II study of gedatolisib in combination with darolutamide in metastatic castration-resistant prostate cancer (mCRPC) [abstract no. 2445P]. Ann Oncol. 2025;36(Suppl 2):S1309\u201386.","journal-title":"Ann Oncol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02394-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02394-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02394-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:57:03Z","timestamp":1792727823000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02394-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":32,"alternative-id":["2394"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02394-y","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"6 September 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Hannah A. Blair is a salaried employee of Adis International Ltd\/Springer Nature and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":1,"name":"Ethics","label":"Authorship and Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}